The company said it will seek an expanded indication for the left atrial appendage closure device after it met all safety and ...

Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrilla ...

Boston Scientific stock tumbled Monday on mixed test results for its Watchman device in patients at risk of having a stroke.

Physicians wrestled with endpoint composition, low event rates, a possible difference in ischemic strokes, and more.

In one of the largest studies of its kind, a trial of Boston Scientific’s small, permanent cardiac implant showed that it could potentially serve as an alternative to long-term blood thin | Boston ...

A device smaller than a quarter is giving heart patients a new lease on life. The Watchman device is implanted in the heart to prevent blood clots from forming without the need of blood thinners. This ...

The study evaluated the company’s Watchman FLX device, designed to reduce stroke risk in patients with non valvular atrial ...

Data for Boston Scientific’s Watchman FLX implant met the primary endpoint in a new study. The stock is falling anyway.

The Cottage Heart & Vascular Center’s structural heart team at Santa Barbara Cottage Hospital (SBCH) recently performed their 1,000th WATCHMAN device procedure, a minimally invasive solution for ...

Boston Scientific (NYSE:BSX) announced new findings from the CHAMPION-AF trial supporting its Watchman FLX system.

MedStar Heart & Vascular Institute now offers patients with irregular heart rhythm a minimally invasive option to reduce the risk of stroke, as well as enable stopping long-term use of blood thinning ...